Affordable Access

deepdyve-link
Publisher Website

Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.

Authors
  • Nelson, Michelle H1
  • Bowers, Jacob S1
  • Bailey, Stefanie R1
  • Diven, Marshall A1
  • Fugle, Caroline W1
  • Kaiser, Andrew D M2
  • Wrzesinski, Claudia2
  • Liu, Bei1
  • Restifo, Nicholas P2
  • Paulos, Chrystal M1
  • 1 Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425 USA.
  • 2 Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892 USA.
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
2016
Volume
4
Pages
6–6
Identifiers
DOI: 10.1186/s40425-016-0110-8
PMID: 26885368
Source
Medline
Keywords
License
Unknown

Abstract

Collectively, our results identify how and when to administer TLR agonists to augment T cell-based immunotherapy in the absence or presence of host preconditioning for treatment of advanced malignancies. Our findings have clinical implications for the design of next generation immune-based therapies for patients with cancer.

Report this publication

Statistics

Seen <100 times